Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYELOCHOL: 18F-choline PET/CT vs 18F-FDG PET/CT in Multiple Myeloma
NCT03891914Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Nov 2019
- Primary completion
- Jan 2023
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluorine-18 fluorocholine in multiple myeloma (MM), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoints: Number of whole-body bone lesions at Day 7 and Number of bone lesions within defined skeletal areas at Day 7. Started Nov 2019; status: completed.
02
Drugs
fluorine-18 fluorocholine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03891914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891914.